Search

Author/Creator Hutson, T.E.

1. 2509 Overall survival analysis from a randomised phase III trial of axitini vs sorafenib as first-line therapy in patients with metastatic renal cell carcinoma. (September 2015)

Authors:
Hutson, T.E.; Al-Shukri, S.; Stus, V.P.; Lipatov, O.N.; Shparyk, Y.; Bair, A.H.; Rosbrook, B.; Andrews, G.I.; Vogelzang, N.J.
Journal:
European journal of cancer
Issue:
Volume 51:(2015)Supplement 3
Page Start:
S476
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Overall survival results from the phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (METEOR). (February 2017)

Authors:
Schmidinger, M.; Motzer, R.J.; Powles, T.; Escudier, B.; Tannir, N.M.; Mainwaring, P.N.; Rini, B.I.; Hammers, H.J.; Donscov, F.; Roth, B.; Peltola, K.; Lee, J.L.; Heng, D.Y.C.; Aftab, D.T.; Hessel, C.; Scheffold, C.; Schwab, G.; Pal, S.; Hutson, T.E.; Choueiri, T.K.
Journal:
European journal of cancer
Issue:
Volume 72(2017)Supplement 1
Page Start:
S187
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search